> Lundbeck offloaded two preclinical programs to AstraZeneca. The deal continues Lundbeck’s push to shed assets that are outside of its area of focus. Statement
> UniQure presented data on its hemophilia B gene therapy program. The data suggest the vector used by uniQure achieves liver transduction in the presence of pre-existing anti-AAV5 neutralizing antibodies. Release
> 4D Pharma gained clearance to trial a commensal bacteria strain in cancer patients. The trial will look at the immunomodulatory effects of MRx0518 in people with solid tumors. Statement
> Sensorion raised €8.7 million ($10.2 million). The money will fund the completion of a phase 2 trial of SENS-111 in patients with rare ear disease vestibular neuritis. Release
> Cellectis gained clearance to increase the dose levels in a phase 1 trial of off-the-shelf CAR-T drug UCART123. The French biotech is also opening another site in a bid to increase the speed of enrollment. Statement